Determining Individualized Cancer Therapy in Pancreatic Cancer

Last updated: April 21, 2025
Sponsor: Medical College of Wisconsin
Overall Status: Active - Recruiting

Phase

N/A

Condition

Digestive System Neoplasms

Treatment

Targeted Therapy

Clinical Study ID

NCT05914987
PRO00048019
  • Ages > 18
  • All Genders

Study Summary

This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥18 years.

  • Pathologically confirmed pancreatic cancer.

  • Ability to understand a written informed consent document and the willingness tosign it

Exclusion

Exclusion Criteria:

  • Age <18 years.

  • Primary cancer diagnosis other than pancreatic cancer.

Study Design

Total Participants: 1000
Treatment Group(s): 1
Primary Treatment: Targeted Therapy
Phase:
Study Start date:
December 04, 2023
Estimated Completion Date:
August 01, 2033

Connect with a study center

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin 53226
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.